Inferra AIResearch Tools

Inferra AI / Company / ALC

Alcon

ALC · Health Care

Last earnings Aug 10, 2026

Key results

EPSquarter

$0.35

Alcon reported diluted earnings per share of $0.35 and core diluted earnings per share 2 of $0.76 in the second quarter of 2025.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Operating marginquarter

9.6%

1 Second-quarter and first-half 2025 key figures Three months ended June 30 Six months ended June 30 2025 2024 2025 2024 Net sales ($ millions) 2,577 2,482 5,028 4,926 Operating margin (%) 9.6% 12.8% 14.2% 13.9% Diluted earnings per share ($) 0.35 0.45 1.06 0.95 Core results (non-IFRS measure) 2 Core operating margin (%) 19.1% 19.8% 19.9% 20.9% Core diluted earnings per share ($) 0.76 0.74 1.50 1.52 Cash flows ($ millions) Net cash flows from operating activities 889 871 Free cash flow (non-IFRS measure) 3 681 667 Second-quarter and first-half 2025 results Reported net sales for the second quarter of 2025 were $2.6 billion, up 4% versus the second quarter of 2024.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Core operating marginquarter

19.1%

1 Second-quarter and first-half 2025 key figures Three months ended June 30 Six months ended June 30 2025 2024 2025 2024 Net sales ($ millions) 2,577 2,482 5,028 4,926 Operating margin (%) 9.6% 12.8% 14.2% 13.9% Diluted earnings per share ($) 0.35 0.45 1.06 0.95 Core results (non-IFRS measure) 2 Core operating margin (%) 19.1% 19.8% 19.9% 20.9% Core diluted earnings per share ($) 0.76 0.74 1.50 1.52 Cash flows ($ millions) Net cash flows from operating activities 889 871 Free cash flow (non-IFRS measure) 3 681 667 Second-quarter and first-half 2025 results Reported net sales for the second quarter of 2025 were $2.6 billion, up 4% versus the second quarter of 2024.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Operating incomequarter

$247 million

Operating income Second quarter Operating income was $247 million (-22%, -26% cc), compared to $318 million in the prior year period.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Operating margin decreased 3.2 percentage points as the current year period included $44 million in charges related to the discontinued commercialization of a Vision Care product and increased investment in research and development ( R D ), including for recent acquisitions.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Excluding a positive 0.3 percentage point impact from currency, operating margin decreased 3.5 percentage points on a constant currency basis.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Adjustments to arrive at core operating income in the current year period were $244 million, mainly due to $173 million of amortization and $44 million of product discontinuation charges.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Adjustments to arrive at core operating income in the prior year period were $173 million, mainly due to $165 million of amortization.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Core operating incomequarter

$491 million

Core operating income was $491 million (0%, -2% cc), in line with the prior year period on a reported basis.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

AI analysis

Q2 2025 · reported Aug 19, 2025

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

EPS · Q2 2025
$0.35
EX-99 · Aug 19, 2025
Operating income · Q2 2025
$247M
-22.3% -$71M vs year ago computed from stated figures
EX-99 · Aug 19, 2025
Operating margin · Q2 2025
9.6%
EX-99 · Aug 19, 2025
Core operating margin · Q2 2025
19.1%
EX-99 · Aug 19, 2025

Headline figures

MetricQ2 2025Prior qtrYear ago
EPS$0.35——
Operating margin9.6%——
Core operating margin19.1%——
Operating income$247 million—$318 million
Core operating income$491 million——

EX-99 · Aug 19, 2025

Guidance · company-stated

Direction: raised

No guidance located in the held release

Stated figure8%

“8 billion, up 8% on a reported basis, or up 7% constant currency 1 (cc), versus second-quarter 2025 Returned $538 million to shareholders through dividends and share repurchases on a year-to-date basis Updated full-year guidance - raised core operating margin and core diluted EPS growth Ad Hoc Announcement Pursuant to Art.”

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Operating margin9.6%
Core operating margin19.1%

Capital allocation

Dividend$166M

Capital returns include the repurchase of approximately 1.4 million shares 4 for $121 million and dividend payments of $166 million.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Alcon reported diluted earnings per share of $0.35 and core diluted earnings per share 2 of $0.76 in the second quarter of 2025

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Capital returns include the repurchase of approximately 1.4 million shares 4 for $121 million and dividend payments of $166 million.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

On February 25, 2025, the Board authorized the repurchase of up to $750 million of the Company s common shares.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Refer to Note 4 of the Condensed Consolidated Interim Financial Statements for details regarding the share repurchase program.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Does not reflect the impact of future share repurchases under the Company's share repurchase program.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Examples of forward-looking statements include, among others, statements we make regarding our 2025 outlook, liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Non-IFRS measures as defined by the Company Alcon uses certain non-IFRS metrics when measuring performance, including when measuring current period results against prior periods, including core results, percentage changes measured in constant currency, EBITDA, free cash flow and net (debt) liquidity.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Strategy & priorities

Forward-looking statements can be identified by words such as anticipate, intend, commitment, look forward, maintain, plan, goal, seek, target, assume, believe, project, estimate, expect, strategy, future, likely, may, should, will and similar references to future periods.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Examples of forward-looking statements include, among others, statements we make regarding our 2025 outlook, liquidity, revenue, gross margin, operating margin, effective tax rate, foreign currency exchange movements, earnings per share, our plans and decisions relating to various capital expenditures, capital allocation priorities and other discretionary items such as our market growth assumptions, our social impact and sustainability plans, targets, goals and expectations, and generally, our expectations concerning our future performance.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Net (debt) liquidity is presented as additional information because management believes it is a useful supplemental indicator of Alcon's ability to pay dividends, to meet financial commitments and to invest in new strategic opportunities, including strengthening its balance sheet.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

This transaction supports Alcon's ophthalmic pharmaceutical portfolio expansion, including biopharmaceutical applications, with the potential to advance the first-ever corneal cell therapy candidate.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Risks & headwinds

prior year (cc) 1 (non-IFRS measure) +2% to +5% 0% to +2% Updated This outlook assumes the following Aggregated markets grow approximately low-single digits Tariff rates and exemptions announced as of August 11, 2025 persist through the end of the year.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

The Company expects a full-year gross tariff impact of approximately $100 million, which is expected to pressure cost of net sales.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

10 Additional Considerations Tariffs Beginning April 2025, the United States government announced additional tariffs on goods imported into the United States, and some nations have responded with reciprocal tariffs and other actions.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Since then, there have been temporary reductions or pauses of certain tariffs to allow for trade negotiations, as well as new tariff announcements.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Additional tariffs incurred in the United States and China during the second quarter of 2025 amounted to $27 million, of which $12 million was recognized in Cost of net sales in the Condensed Consolidated Income Statement and $15 million was recognized in Inventories in the Condensed Consolidated Balance Sheet as of June 30, 2025.

SEC original ↗Alcon — Earnings release (6-K exhibit)EX-99Aug 19, 2025

Documents

Earnings deck slides

1 deck with slide view

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health CareJohnson & Johnson (JNJ) Health Care

Filings

89 documents

Earnings releases

56 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Alcon are held in this edition of the library.

Mentioned by

10 companies

Other tracked companies whose held documents mention Alcon by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.